TARA (Protara Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TARA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Jesse Shefferman | CEO and President | MIXED | — | — |
| 2026-06-16 | Barry P Flannelly | Director | A | — | — |
| 2026-06-16 | Cynthia Smith | Director | A | — | — |
| 2026-06-16 | Michael Edward Solomon | Director | A | — | — |
| 2026-06-16 | Richard S Levy | Director | A | — | — |
| 2026-06-16 | Jane Huang | Director | A | — | — |
| 2026-06-16 | GREGORY SARGEN | Director | A | — | — |
| 2026-06-16 | LUKE M BESHAR | Director | A | — | — |
| 2026-06-16 | ROGER GARCEAU | Director | A | — | — |
| 2026-06-03 | WILLIAM CONKLING | Chief Commercial Officer | F | — | — |
| 2026-04-09 | Jacqueline Zummo | Chief R&D Officer | Sell | — | — |
| 2026-04-02 | Jacqueline Zummo | Chief R&D Officer | Sell | — | — |
| 2026-01-27 | Patrick Fabbio | Chief Financial Officer | F | — | — |
| 2026-01-27 | Jesse Shefferman | CEO and President | F | — | — |
| 2026-01-27 | Hannah Fry | VP, Controller | F | — | — |
| 2026-01-27 | Jacqueline Zummo | Chf Scientific Operations Off | F | — | — |
| 2026-01-22 | Hannah Fry | VP, Controller | F | — | — |
| 2026-01-22 | Jacqueline Zummo | Chf Scientific Operations Off | F | — | — |
| 2026-01-22 | Patrick Fabbio | Chief Financial Officer | F | — | — |
| 2026-01-22 | Jesse Shefferman | CEO and President | F | — | — |
| 2026-01-21 | Patrick Fabbio | Chief Financial Officer | A | — | — |
| 2026-01-21 | Leonardo Viana Nicacio | Chief Medical Officer | A | — | — |
| 2026-01-21 | WILLIAM CONKLING | Chief Commercial Officer | A | — | — |
| 2026-01-21 | Jacqueline Zummo | Chf Scientific Operations Off | A | — | — |
| 2026-01-21 | Jesse Shefferman | CEO and President | A | — | — |
| 2026-01-21 | Hannah Fry | VP, Controller | A | — | — |
| 2025-07-07 | Jesse Shefferman | CEO and President | G | — | — |
| 2025-06-30 | Jesse Shefferman | CEO and President | G | — | — |
| 2025-06-13 | Richard S Levy | Director | A | — | — |
| 2025-06-13 | Jane Huang | Director | A | — | — |
| 2025-06-13 | Michael Edward Solomon | Director | A | — | — |
| 2025-06-13 | LUKE M BESHAR | Director | A | — | — |
| 2025-06-13 | GREGORY SARGEN | Director | A | — | — |
| 2025-06-13 | Cynthia Smith | Director | A | — | — |
| 2025-06-13 | Barry P Flannelly | Director | A | — | — |
| 2025-06-13 | ROGER GARCEAU | Director | A | — | — |
| 2025-06-04 | WILLIAM CONKLING | Chief Commercial Officer | A | — | — |
| 2025-05-19 | Richard S Levy | Director | Buy | — | — |
| 2025-05-16 | Richard S Levy | Director | Buy | — | — |
| 2025-04-17 | Leonardo Viana Nicacio | Chief Medical Officer | A | — | — |
| 2025-03-28 | Jacqueline Zummo | Chf Scientific Operations Off | Sell | — | — |
| 2025-03-28 | Hannah Fry | VP, Controller | — | — | — |
| 2025-03-28 | Jacqueline Zummo | Chf Scientific Operations Off | — | — | — |
| 2025-03-28 | Jesse Shefferman | CEO and President | — | — | — |
| 2025-03-28 | Patrick Fabbio | Chief Financial Officer | — | — | — |
| 2025-01-28 | Patrick Fabbio | Chief Financial Officer | A | — | — |
| 2025-01-28 | Hannah Fry | VP, Controller | A | — | — |
| 2025-01-28 | Jesse Shefferman | CEO and President | A | — | — |
| 2025-01-28 | Jacqueline Zummo | Chf Scientific Operations Off | A | — | — |
| 2025-01-23 | Hannah Fry | VP, Controller | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO and President | 991,832 | — |
| — | 10%+ Owner | 782,238 | — |
| — | 10%+ Owner | 586,074 | — |
| — | Director | 198,000 | — |
| — | Chief R&D Officer | 94,827 | — |
| — | Chief Medical Officer | 78,181 | — |
| — | Chief Commercial Officer | 69,992 | — |
| — | Chief Financial Officer | 64,115 | — |
| — | Chief Medical Officer | 56,704 | — |
| — | 10%+ Owner | 51,500 | — |
| — | Director | 51,000 | — |
| — | Chief Medical Officer | 45,500 | — |
| — | VP, Controller | 42,723 | — |
| — | Director | 33,000 | — |
| — | Director | 31,000 | — |
| — | Director | 26,500 | — |
| — | Director | 26,500 | — |
| — | Chief Financial Officer | 20,662 | — |
| — | Chief Medical Officer | 9,410 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TARA quote page; the site-wide leaderboard is on the insider transactions hub.